TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.
about
Self-assembled micelles of novel amphiphilic copolymer cholesterol-coupled F68 containing cabazitaxel as a drug delivery systemDrug costs in the management of metastatic castration-resistant prostate cancer in Canada.Chemotherapy for prostate cancer: Clinical practice in Canada.Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial.Brachyury as a potential modulator of androgen receptor activity and a key player in therapy resistance in prostate cancer.Cabazitaxel: a guide to its use in hormone-refractory metastatic prostate cancer.Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal.Evolution of the treatment paradigm for patients with metastatic castration-resistant prostate cancer.The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.Clinical perspectives: practical insights from clinical experience with cabazitaxel in Australia.Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer.Value of treatment in clinical trials versus the real world: the case of abiraterone acetate (Zytiga) for postchemotherapy metastatic castration-resistant prostate cancer patients in Sweden.Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy.Clinical Efficacy of TroVax in the Treatment of Progressive Castration-resistant Prostate Cancer.Determination of 6258-70, a new semi-synthetic taxane, in rat plasma and tissues: Application to the pharmacokinetics and tissue distribution study.[Metastatic castration-resistant prostate cancer : Use of cabazitaxel taking into consideration current data].[Metastatic prostate cancer : Update: position paper for the use of chemotherapy].Treatment in the STAMPEDE era for castrate resistant prostate cancer in the UK: ongoing challenges and underappreciated clinical problems.Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines.Physicochemical stability of cabazitaxel and docetaxel solutions
P2860
Q33633314-D48386A5-F018-4AB0-853C-187B5B08A354Q33904772-FF4268E1-CEAA-405D-9BDF-0439ACF4835FQ36838375-C6E9773E-5702-455E-AA67-5D395A7A2E00Q37126921-40E8DBDE-0874-4E23-8C50-28EC2B9CBBDDQ37301697-EC6C306F-8685-48C4-8CD7-F3A59BA1D793Q38093471-53204FDE-707F-422D-9A09-C17DE8A37C7EQ38098484-83DBBF75-F314-4E04-AF2D-0BC4407D305DQ38166255-94E57C98-3B11-4A29-935A-A4BB3462661CQ38374417-39A9D257-2347-4C2F-865C-F0EB43B3F3F8Q38412864-4BAEF520-9E26-48D4-9645-697FA84F9A86Q38756919-BAFEBC7B-9D51-4F75-A8DB-3A6D5BE976C4Q38816353-2966942C-259B-483A-A81E-5B71439C3AB2Q39183360-C6AEDAC7-9E2C-4AF9-A9F2-D1CF82D70F1EQ40357390-77992B76-0DA6-40C5-BCBA-06453123B0A6Q49265725-BD599C44-ECD5-46DA-80DF-3D2231930F59Q50085962-4AE00C15-EB92-49DA-9796-879C1C4FF8ECQ52837349-D3BA5685-6E3B-4A9C-BB0A-651EEE872ADAQ55285232-71462C78-5A61-45AC-B745-1202908FF9FAQ55379433-737A8F1D-4457-4DFA-AD12-35CC1BB5E3CFQ57951097-21C6C201-9672-45A7-9CF7-8C091EF25772
P2860
TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
TROPIC: Phase III trial of cab ...... ion-resistant prostate cancer.
@en
TROPIC: Phase III trial of cab ...... ion-resistant prostate cancer.
@nl
type
label
TROPIC: Phase III trial of cab ...... ion-resistant prostate cancer.
@en
TROPIC: Phase III trial of cab ...... ion-resistant prostate cancer.
@nl
prefLabel
TROPIC: Phase III trial of cab ...... ion-resistant prostate cancer.
@en
TROPIC: Phase III trial of cab ...... ion-resistant prostate cancer.
@nl
P2860
P356
P1433
P1476
TROPIC: Phase III trial of cab ...... ion-resistant prostate cancer.
@en
P2093
Stephane Oudard
P2860
P304
P356
10.2217/FON.11.23
P407
P577
2011-04-01T00:00:00Z